Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing

Anti-CD20 antibodies such as rituximab are broadly used to treat B-cell malignancies. These antibodies can induce various effector functions, including immune cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Neutrophils can induce ADCC toward solid cancer cells by trogoptosis, a cytoto...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rees, Dieke J., Brinkhaus, Maximilian, Klein, Bart, Verkuijlen, Paul, Tool, Anton T.J., Schornagel, Karin, Treffers, Louise W., van Houdt, Michel, Kater, Arnon P., Vidarsson, Gestur, Gennery, Andrew R., Kuijpers, Taco W., van Bruggen, Robin, Matlung, Hanke L., van den Berg, Timo K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006259/
https://www.ncbi.nlm.nih.gov/pubmed/34942000
http://dx.doi.org/10.1182/bloodadvances.2021005367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006259/
https://www.ncbi.nlm.nih.gov/pubmed/34942000
http://dx.doi.org/10.1182/bloodadvances.2021005367

Ejemplares similares